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Somatic driver mechanisms of pituitary adenoma pathogenesis have remained incompletely characterized and 24 
apart from mutations in the stimulatory Gα protein (Gαs encoded by GNAS) resulting activated cAMP 25 
synthesis, pathogenic variants are rarely found in growth hormone-secreting pituitary tumors 26 
(somatotropinomas). 27 
The purpose of the current work was to clarify how genetic and epigenetic alterations contribute to the 28 
development of somatotropinomas by conducting an integrated copy-number alteration, whole-genome- and 29 
bisulfite sequencing, and transcriptome analysis of 21 tumors. Somatic mutation burden was low but 30 
somatotropinomas formed two subtypes associated with distinct aneuploidy rates and unique transcription 31 
profiles. Tumors with recurrent chromosome aneuploidy (CA) were GNAS mutation negative (Gsp-). The 32 
chromosome stable (CS) –group contained Gsp+ somatotropinomas and two totally aneuploidy-free Gsp- 33 
tumors. Genes related to the mitotic G1/S-checkpoint transition, were differentially expressed in CA- and CS-34 
tumors indicating difference in mitotic progression. Also pituitary tumor transforming gene 1 (PTTG1), a 35 
regulator of sister chromatid segregation, showed abundant expression in CA-tumors. Moreover, 36 
somatotropinomas displayed distinct Gsp genotype-specific methylation profiles. Expression quantitative 37 
methylation (eQTM) analysis revealed that inhibitory Gα (Gαi) –signaling is activated in Gsp+ tumors. 38 
These findings suggest that in Gsp- somatotropinomas aneuploidy through modulated driver pathways may be 39 
a causative mechanism for tumorigenesis, whereas Gsp+ tumors in response to mitogenic cAMP-signaling 40 
caused by GNAS mutation are characterized by DNA methylation activated Gαi –signaling. 41 
Significance: These findings provide valuable new information about subtype-specific pituitary tumorigenesis 42 





Pituitary adenomas are common and comprise 15% of all diagnosed intracranial neoplasms. The overall rate 46 
of pituitary tumors in the general population is one case in 1064 [1]. The most common functioning pituitary 47 
tumors hypersecrete prolactin (PRL) (40%). Growth hormone (GH) –secreting adenomas (somatotropinomas) 48 
constitute 15-20%, and usually lead to increased height (gigantism) in children or adolescents. In adults, 49 
hypersecretion of GH causes acromegaly, and leads to overgrowth of bone and cartilage, insulin resistance, 50 
hypertension, cardiovascular and respiratory complications, and increased risk of neoplasms. Despite being 51 
benign, excess GH production is associated with increased morbidity and reduced life expectancy [2, 3, 4].  52 
The majority of pituitary adenomas arise in a sporadic setting and are considered to be unicellular in origin. 53 
As in other neoplasms, pituitary tumor formation and dysregulated hormone secretion are results of series of 54 
genetic and epigenetic alterations upsetting the balance between proliferation and apoptosis. The most 55 
frequently described somatic pathogenic events occurring in somatotropinomas are gain-of-function mutations 56 
in the stimulatory guanine nucleotide (GTP) binding protein alpha (Gαs) encoded by the GNAS gene. This 57 
Gsp oncogene contributes to constitutive synthesis of cyclic adenosine monophosphate (cAMP), activation of 58 
protein kinase A (PKA) pathway, and subsequent tumor formation. Gsp mutations occur in ~35% of 59 
somatotropinomas [5, 6]. Next generation sequencing has shown that the somatic background of pituitary 60 
adenomas is calm and single nucleotide- (SNV) and structural variants (SV) are rarely found. Therefore, the 61 
exact mechanisms of tumorigenesis often remain unknown [7, 8, 9, 10, 11, 12]. 62 
Numerical alterations of whole chromosomes, aneuploidy, is observed in a subset of pituitary tumors [8, 12]. 63 
Aneuploidy is frequently noted in solid and malignant tumors and is often associated with tumor recurrence 64 
and drug resistance in some tumor types [13, 14]. Shuffling of genomic content through aneuploidy facilitates 65 
loss of heterozygosity (LOH) of tumor suppressors and increases copy number of oncogenes and can constitute 66 
a powerful driver for tumor progression. In addition, epigenetic modifications associated to changes in gene 67 
expression are considered potential causes of pituitary tumor initiation and development [15]. 68 
Apart from the Gsp+ driver mutation, mechanisms of pituitary adenoma pathogenesis have remained 69 
incompletely characterized, and improved understanding of uncontrolled cell growth associated with pituitary 70 
tumors is required. The purpose of the current work was to clarify how somatic alterations drive development 71 
of somatotropinomas and discover subgroup-specific somatic patterns. This was done by dissecting 72 
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associations between somatic copy number alterations (SCNA), gene expression and DNA methylation in 73 
GNAS mutation negative (Gsp-) and positive (Gsp+) pituitary tumors. In addition, whole genome sequencing 74 
(WGS) was performed to identify somatic SNV and SV changes.  75 
Here we found that somatotropinomas form two tumor subtypes associated with distinct aneuploidy rates and 76 
transcription profiles. Our results indicate that defective chromosomal segregation may underlie the 77 
development of aneuploidy and tumor initiation in a subset of Gsp- somatotropinomas. Further, we show that 78 
Gsp mutation status is the major determinant of methylation profiles of somatotropinomas, and that 79 
methylation regulated transcription activates an adaptive response to elevated cAMP levels in Gsp+ tumors.  80 
Material and Methods 81 
Patient material 82 
We studied somatotropinomas from twenty one patients (13 males and 8 females, mean age at diagnosis 43 83 
years [range 14-69 years]) (Table 1). The tumor samples were collected between 2009 and 2015 at the Helsinki 84 
University Hospital and frozen while fresh. The study was approved by the Ethics Committee of the Hospital 85 
district of Helsinki (Dnr. 408/13/03/03/2009). All patients had given informed consent for sample collection 86 
and analysis. In the case of minor, a parent gave the consent. All research conformed with the principles of the 87 
Declaration of Helsinki. The tumor percentages (>95%) were verified with hematoxylin and eosin stainings. 88 
All patients were mutation negative for the established germline mutations associated with pituitary neoplasia 89 
(Supplementary Methods). Seven tumors were Gsp+ and 14 tumors Gsp-. Seven patients have hormonally 90 
active disease and are treated with post-operative somatostatin analogue therapy (ST3, ST6, ST13, ST16, 91 
ST17, ST19, ST21), one (ST6) of them is on somatostatin-cabergoline combination therapy and two (ST3, 92 
ST17) on somatostatin-pegvisomant combination therapy. Currently, 14 patients are in hormonal remission, 93 
while three non-compliant patients (ST3, ST7, ST22) are not, and current medical therapy of four patients 94 
(ST2, ST8, ST14, ST15) is not known (Table 1).  95 
WGS, SCNA and gene expression profiling 96 
Genomic DNA was extracted by FastDNA Spin Kit (MP Biomedicals) (tumors) and DNeasy Blood and Tissue 97 
Kit (Qiagen) (blood). The AIP and Gsp mutation status was identified by capillary sequencing as described 98 
earlier [6]. The WGS genomic DNA libraries were prepared according to Illumina PE sequencing protocols 99 
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and sequenced to at least 40x median coverage on the Illumina HiSeq 2000 platform (2x100bp PE) (Beijing 100 
Genomics Institute, BGI Tech Solutions Co., Ltd., China). A genome-wide analysis of tumors for somatic 101 
SNVs and SVs was performed as described previously [8]. The somatic variants in tumors ST2-12 were 102 
identified by filtering against a patient-matched blood sample. For the Gsp- tumors ST13, ST16, ST18-ST20 103 
and ST22, patient-matched germline variants were not available, and somatic variants were identified by 104 
filtering against all variants in gnomAD (r2.0.1) (https://gnomad.broadinstitute.org), 1000 genomes project 105 
(phase 3, 20130502) (http://www.internationalgenome.org/home), Sequencing Initiative Suomi (SISu, 106 
accessed on March 2016) ( http://www.sisuproject.fi/) and an in-house collection of 339 normal tissue WGS 107 
samples. The remaining variants were filtered to a minimum coverage of 10 reads, minimum alternative allele 108 
coverage of six, and minimum quality score of 40 (phred-scale). 109 
SCNA analysis was performed using SNP arrays (1kGP HumanOmni2.5-8 BeadChip, Illumina, Inc.). Analysis 110 
was performed as described previously [8] comparing individuals’ tumor sample to its corresponding normal 111 
blood derived DNA using Genomics Suite v.6.5 (Partek) with a GC-wave correction. Genomic instability 112 
percentage (GI%) was determined by dividing the number of altered chromosomal arms in the tumor by the 113 
total number of chromosomal arms. 114 
RNA was extracted with RNeasy Mini Kit (Qiagen). Expression profiles were generated using GeneChip™ 115 
Human Transcriptome Array 2.0 array (Thermo Fisher Scientific). cDNA synthesis, labeling, and 116 
hybridization was performed according to the manufacturer’s instructions. Quality control, normalization, and 117 
analysis of data were carried out using Transcriptome Analysis Console v 3.0 (Thermo Fisher Scientific). 118 
Unsupervised hierarchical clustering of 1000 probes with the largest variance was done using cosine distance 119 
with bottom-up average linking. The annotation file HTA-2_0.na35.2.hg19.transcript and ANOVA were used 120 
to determine differentially expressed genes between tumor groups. Differentially expressed genes were filtered 121 
using false discovery rate (FDR)< 5% and fold change |FC| > 2. 122 
Bisulfite sequencing and data processing 123 
The target region bisulfite sequencing (TBS) of somatotropinomas was performed utilizing the SureSelectXT 124 
Human Methyl. Seq (Agilent Technologies, Inc.) target enrichment system. Illumina paired-end sequencing 125 
for libraries was done using 126 base-pair read length and the HiSeq2500 platform (Illumina, Inc.) (Beijing 126 
Genomics Institute, BGI Tech Solutions Co., Ltd.). 127 
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The raw TBS data were preprocessed with the bismark (v0.16.3) pipeline, bowtie2 (v2.3.0) and the human 128 
reference genome (UCSC hg19). A total of 8,493,667 CpGs were observed with a minimum coverage of two, 129 
out of which 4,527,285 CpGs passed the minimum coverage in at least four tumors. CpG methylation levels 130 
were quantified using bsseq (v1.10.0) and DSS (v2.14.0) as follows. An unsupervised, genome-wide analysis 131 
was done using bsseq quantification of the CpG methylation levels: the TBS target regions (N=350,539) were 132 
filtered to a minimum of three CpGs that passed minimum coverage (N=198,649). The default bsseq 133 
smoothing was applied to quantify the methylation level of each target region. An unsupervised hierarchical 134 
clustering of 50 000 TBS regions with the largest variance was done using cosine distance with bottom-up 135 
average linking. Supervised analysis of differentially methylated regions (DMRs) used the default DSS 136 
smoothing to test for a minimum mean methylation difference of 0.2 in a two-group comparison. The DMRs 137 
were filtered with the default DSS settings (a minimum of 3 CpGs, minimum 50 bps and P<10-5). 138 
The gene annotation and their genomic coordinates were based on Ensemble (v82, hg19). The promoter regions 139 
were defined as going from −1kb to +2kb relative to the transcription starting site (TSS), gene bodies (+2kb, 140 
relative to the TSS, to the end of the gene). Other genomic annotations were downloaded from the UCSC table 141 
browser (accessed on August 2017) for ENCODE enhancer regions (6 human cell lines; awg segmentation 142 
combined), DNaseI Hypersensitivity Clusters (ENCODE v3), ENCODE transcription factor clusters (TFBS 143 
clusters v3; 161 factors) including the CCCTC-binding factor (CTCF) sites, and CpG islands [16]. CpG island 144 
shores were composed of 2kb upstream and downstream regions flanking the CpG islands. Methylation 145 
differences with regards to replication timing were annotated based on HeLa cell line data [17].  146 
CpG methylation levels were quantified within [0, 1], where 0 and 1 correspond to total absence and presence 147 
of the mark respectively.  148 
Expression quantitative methylation (eQTM) analysis 149 
eQTM analysis was used to identify association between methylation and gene expression levels. The DMRs 150 
and their nearby genes were tested for association, also known as cis-eQTM [18], using MatrixEQTL (v2.1.1). 151 
The cis-eQTMs were filtered to a maximum 20 Kbp distance between the gene and DMR. The resulting 152 
associations were filtered to FDR< 5%.  153 
Pathway analyses 154 
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The pathway data was generated with Ingenuity Pathways Analyses (IPA) software 155 
(https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis. IPA Summer 2018 Release). 156 
The data was mapped into relevant pathways based on their functional annotation and known molecular 157 
interactions in Ingenuity’s Knowledge Base (IPKB). The -log of p-value were calculated by Fisher's exact test. 158 
A data set derived from expression arrays along with the corresponding FC and FDR p-values was uploaded 159 
into IPA. The eQTM data set was mapped into relevant pathways in a similar manner. 160 
Immunohistochemistry (IHC) 161 
KI-67 (MIB-1) and PTTG1 (pituitary tumor transformation gene 1) IHCs were performed as described earlier 162 
[8]. Other antibodies used were protein tyrosine phosphatase, receptor type D (PTPRD) rabbit Anti-PTPRD 163 
(HPA054829, 1:300) (Sigma-Aldrich), protein tyrosine phosphatase, receptor type K (PTPRK) rabbit Anti-164 
PTPRK (HPA054822, 1:400) (Sigma-Aldrich), retinoblastoma (RB1) rabbit Anti-RB1 (HPA050082, 1:500) 165 
(Sigma-Aldrich) and anti-Rb (phosphor-S780) (ab47763, 1:70) (Abcam). Anti-mouse/rabbit/rat secondary 166 
antibody, Poly-HRP-GAM/R/R (DPVB55HRP, Immunologic) and DAB chromogen (Thermo Fisher 167 
Scientific) were used for detection.  Ki-67 and PTTG1 scores were obtained by calculating the average 168 
percentage of stained cells among the tumor cell population. PTPRD, PTPRD and RB1 proteins were scored 169 
by evaluating fractions of immunopositive cells and staining intensities. For scoring details see the 170 
Supplementary Methods. 171 
Availability of data and materials 172 
Data has been deposited at the European Genome-phenome Archive (EGA) hosted by the EBI and the CRG, 173 
under accession number EGAS00001003488. 174 
RESULTS 175 
Somatic SNV and indel background of Gsp- somatotropinomas 176 
The somatic landscape of the tumors ST2-ST12 was reported previously [8]. The tumors had an average of 2.3 177 
coding region SNVs per tumor, with GNAS being the only recurrently mutated gene. Here we examined the 178 
somatic SNVs and SVs of six additional Gsp- tumors: ST13, ST16, ST18-20, and ST22. Supplementary Table 179 
S1 gives all the coding region (missense, premature stop codon, frameshift) variants that passed the somatic 180 
filtering. These additional Gsp- tumors had an excess of somatic variants - in total 92 coding region SNVs and 181 
on average 15.3 SNVs per tumor – simply because rare germline variants may have passed the population-182 
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based filtering. The majority of the somatic variants (47 SNVs) arise from ST22 due to patient’s Italian 183 
ancestry being underrepresented among the population-based controls. Among the 21 tumors studied the only 184 
recurrently mutated gene was GNAS. No focal deletions or complex chromosomal rearrangements were 185 
observed with exception of ST3, a previously reported Gsp+ tumor [8] (Supplementary Fig. S1). 186 
SCNA and expression profiling differences in CA- and CS -tumors 187 
Data from 21 somatotropinoma normal/tumor pairs was used for SCNA analysis. Results of eleven 188 
normal/tumor pairs were from our earlier work [8]. Analyses revealed that 12 Gsp- tumors contained frequent 189 
and recurrent (≥4 tumors share the event) chromosomal deletions (chr 1, 4, 6, 14, 15, 16, 18, 22). Also gains 190 
(chr 5, 7, 9, 19, 20) of entire chromosomes were detected, although with considerably lower frequency 191 
(Supplementary Fig. S1). Copy neutral LOH or homozygous deletions were not observed. All detected 192 
chromosomal gains were duplications of a single chromosome. Gsp+ tumors contained limited amount of 193 
aneuploidy, mostly gains of single chromosomes. An exception was a tumor ST4 with genetic instability (GI%) 194 
22% (Table 1, Supplementary Fig. S1). In addition, two Gsp- tumors (ST5 and ST6) were totally aneuploidy-195 
free. GI% did not correlate with clinical variables (Supplementary Table S2). The observed recurrent 196 
aneuploidy indicates selective advantage during tumorigenesis rather than random copy number alteration 197 
(permutation test P < 10-4; Supplementary Fig. S2). 198 
An unsupervised hierarchical clustering analysis of gene expression demonstrated that aneuploidy was the 199 
major determinant of somatotropinoma subtypes. Tumors clustered according to the aneuploidy rate as follows 200 
(Figure 1A; principal components analysis in Supplementary Fig. S3). Twelve Gsp- tumors with aneuploidy, 201 
from now on called CA (chromosome aneuploidy)-tumors, clustered together. Accordingly, chromosome 202 
stable (CS)-tumors with limited amount or no aneuploidy (7 Gsp+ and 2 Gsp-) formed their own distinct group. 203 
When comparing expressions between CA- and CS-tumors, 881 differentially expressed transcripts (FDR< 204 
5%, |FC|> 2) were identified (Supplementary Table S3). Integration of expression and SCNA data revealed 205 
that 69.8% of differentially expressed transcripts locate at chromosomes with recurrent aneuploidy (≥ 4 tumors 206 
with shared aneuploidy) from which 81.6% positively correlate with the chromosomal copy number change. 207 
To understand the biological relevance of differentially expressed genes in CA-somatotropinomas, pathway 208 
analysis was performed. The top canonical pathway emerged from the tumor subtype-specific expression was 209 
9 
 
the PKA pathway (Figure 1B, Supplementary Table S4). In this cAMP-mediated signaling pathway a majority 210 
of molecules were upregulated in CS-tumor group indicating activated PKA signaling (Figure 2, Table 2). The 211 
major inhibitors of cAMP levels [19], phosphodiesterases (PDEs) were up-regulated in CS-tumor group and 212 
seven protein tyrosine phosphatase (PTP) receptors were differentially expressed between tumor groups (Table 213 
2). 214 
The expression pathway analysis also highlighted several pathways associated with cell cycle regulation and 215 
explicitly in the retinoblastoma 1/E2F transcription factor (RB1/E2F) - mediated G1/S-checkpoint transition. 216 
Among the enriched pathways were Molecular Mechanisms of Cancer, Chronic Myeloid Leukemia, Glioma, 217 
Glioblastoma Multiforme, and Cell Cycle: G1/S Checkpoint Regulation (Figure 1B, Supplementary Table S4). 218 
The genes showing expression differences between tumor groups accumulated in the RB1/E2F -mediated cell 219 
cycle regulation and the subsequent G1/S-checkpoint transition indicating difference in mitotic progression 220 
(Figure 1C.). E2F4 transcription factor, a regulator of cell cycle [20], was downregulated in CA-tumor group. 221 
By contrast, histone deacetylase 5 (HDAC5) and RB transcriptional corepressor like 1 (RBL1/p107), both 222 
repressors of E2F family members, were upregulated in CA-tumor group when compared to CS-tumors. Also 223 
the anti-mitogenic growth factor TGFβ2/SMAD3 signaling was downregulated in CA-tumor group (Figure 224 
1C, Table 3). 225 
Immunohistochemistry 226 
Because RB1 is the major component of the complex regulating G1/S phase transition, protein levels of total- 227 
and phosphorylated-RB1 were semiquantitatively assessed in tumors using immunohistochemistry. In all 228 
tumors >90% of nuclei showed positive total- and phospho-RB1 staining. Because fractions of stained cells 229 
were comparable between tumor groups, staining intensities were compared. Both tumor groups showed weak 230 
to moderate nuclear immunoreactivity of total-RB1 (CA vs CS, 1.67 vs 1.78, p = 0.6, Student´s t-test). In 231 
addition, some occasional cytoplasmic total-RB1 staining was detected in both tumor groups. Phospho-RB1 232 
showed weak to moderate nuclear staining in both tumor groups (1.59 vs 1.67, p = 0.71) (Supplementary Table 233 
5, Supplementary Fig. S4). 234 
To test PKA pathway analysis findings (Figure 2) at the protein levels, PTPRD and PTPRK IHCs were 235 
performed. Tumor material was available from four CA- (ST10, ST12, ST18, ST19) and three CS-tumors 236 
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(ST15, ST17, ST21). In immunopositive tumors both PTPRD and PTPRK localized mainly in cytoplasm and 237 
>90% of cells gave positive staining. PTPRD showed negative immunostaining in CA-tumors (Gsp-) and 238 
moderate immunoreactivity in CS-adenomas (Gsp+). PTPRK immunostaining was negative or weak in CA-239 
tumors and moderate in CS-tumors (Supplementary Fig. 5). 240 
To investigate the role of PTTG1 in the formation of aneuploidy, PTTG1 and Ki-67 immunostainings were 241 
performed. Ki-67 and PTTG1 stainings were detected in all tumors. Ki-67 gave nuclear immunostaining. 242 
PTTG1 immunopositive cells showed both nuclear and cytoplasmic localization. Most of the cells showed 243 
predominant cytoplasmic localization, although there were also cells with predominant nuclear staining in both 244 
tumor groups (Supplementary Fig. S6). All stained cells were scored and number of immunopositive cells were 245 
significantly more abundant in CA-tumors compared to CS-adenomas (x̅ =1.8±1 vs. 0.9±0.5, P=0.016, 246 
Wilcoxon-Mann-Whitney) (Table 1). The PTTG1 RNA expression levels, emerging mainly from non-247 
proliferating cells, were comparable between CA- and CS-tumor groups (FC 1.05, p=0.733). There were no 248 
significant difference in Ki-67 scores between tumor groups (x̅ =2.7±1.6 vs. 1.7±1.2, P=0.27) (Table 1), but 249 
as seen earlier [8, 21] the PTTG1 protein levels correlated with Ki-67 scores (r =0.62, P = 0.002, Pearson`s 250 
coefficient). 251 
DNA methylation 252 
We surveyed DNA methylation and differentially methylated regions (DMRs) in 21 somatotropinomas by 253 
targeted bisulfite sequencing (Supplementary Table S6). An unsupervised clustering of 50 000 CpG regions 254 
with the largest variance between tumors showed, that apart from ST7 and ST21, the tumors clustered 255 
according to the Gsp mutation status (Figure 3A; principal components analysis in Supplementary Fig. S7). 256 
The genome-wide distributions of CpG methylation levels for different genomic contexts revealed that 257 
methylation levels of promoter regions were comparable across tumors (Figure 3A). The rest of the annotated 258 
regions showed hypomethylation of Gsp+ tumors (see below for the supervised analysis of Gsp+ and Gsp-). 259 
Eighteen percentage of the differentially expressed (CA- vs CS) transcripts (119/670 coding transcript clusters; 260 
Supplementary Table S3) were correlated with DNA methylation. 261 
DNA methylation patterns are maintained and regulated by DNA methyltransferases (DNMTs), including 262 
DNMT1, DNMT3A and DNMT3B [22]. We examined tumor-specific associations of DNMT expressions and 263 
median CpG methylation and found that CpG methylation rates correlated with the DNMT1 expression 264 
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(Spearman's rank correlation 0.49, p= 0.025) (Supplementary Fig. S8), while DNMT3A (0.02, p= 0.929) and 265 
3B (0.24, p= 0.294) did not show correlation. 266 
DNA methylation associates also with replication timing [17].  Supplementary Fig. S9 shows an overview of 267 
CpG methylation at different quartiles of replication timing. Majority of the tumors displayed the expected 268 
hypomethylation of late replicating regions (Spearman rho < 0 and P< 0.019; Supplementary Table S7). The 269 
Gsp- tumors ST10, ST11, ST16, and ST20 had an outstanding, positive correlation to replication time 270 
(Spearman rho >0 and P< 0.018), which suggests methylation maintenance also at late replicating regions. No 271 
clinical associations were found to explain the methylation maintenance difference in these four tumors (Table 272 
1). 273 
Because the Gsp mutation status was the major factor behind the DNA methylation rates and profiles across 274 
tumors, DMRs were determined between Gsp+ versus Gsp- somatotropinomas. Altogether, we found 1 369 275 
DMRs out of which 1 339 (97.8%) were hypomethylated in Gsp+ tumors: see Supplementary Table S8 for a 276 
complete list of all 1 369 regions’ genomic coordinates and annotation of nearby (-20Kbp upstream; 2Kbp 277 
downstream) genes (1560 gene annotations). The Supplementary Table S8 is sorted by the absolute value of 278 
the test statistic, where negative effect direction denotes hypometylation among the Gsp+ tumors compared to 279 
the Gsp- tumors. Both the outstanding number of DMRs and the enrichment of Gsp+ tumors towards 280 
hypomethylation can likely be attributed to the genome-wide CpG methylation characteristics between the 281 
tumor types (see the unsupervised analysis and Figure 3A). The DMRs did not enrich among the aneuploidy 282 
chromosomes; 51% of the DMRs reside at recurrent aneuploidy, while the expected proportion was 55% based 283 
on the distribution of the TBS regions. 284 
In addition to the DMR analysis, we also examined the genome-wide methylation profiles between Gsp+ and 285 
Gsp- tumors in different genomic contexts. Supplementary Fig. S10 displays the CpG methylation levels in 286 
the context of promoters, enhancers, CpG islands and CCCTC-binding factor (CTCF) sites. The only 287 
systematic difference between the Gsp+ and Gsp- tumors at these genomic contexts was the overall 288 
hypomethylation in Gsp+ tumors. 289 
To assess the DNA methylation-expression association, the CpG methylation data was integrated with matched 290 
transcriptomes by expression quantitative trait methylation (eQTM) analysis [23, 24]. Consistent with previous 291 
studies, these associations account for only a small fraction of the assayed CpG sites and expressed genes [24]. 292 
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In a supervised comparison, the differentially methylated regions between Gsp+ and Gsp- tumors resulted in 293 
a total of 400 DMR regions with significant (FDR< 0.05) expression to methylation eQTMs pertaining 155 294 
genes (Supplementary Table S9; see the Supplementary Fig. S11 for an unsupervised analysis of eQTMs). 295 
Altogether, 392 DMR regions (98%), were hypomethylated in Gsp+ tumors and from these 333 (84.9%) 296 
showed positive eQTM+ association (hypomethylated in Gsp+ together with gene underexpression in Gsp+). 297 
This enrichment can be attributed mostly to the tumor subtype-specific differences in CpG methylation 298 
characteristics at gene body regions (Figure 3A). 299 
To identify biological functions associated with the methylation difference between Gsp+ and Gsp- 300 
somatotropinomas, we performed pathway analysis from the eQTM gene list. The majority of emerged 301 
pathways (22/31) were associated with inhibitory Gα protein (Gαi)– and/or voltage-gated calcium channel 302 
(CaCn) signaling (Figure 3B, Supplementary Table S10). Both Gαi and Ca2+ signaling are previously 303 
connected to pituitary neoplasia [25, 26]. The inhibitory G protein subunit alpha I-2 (GNAI2; Gαi-2) and G 304 
protein subunit beta 1 (GNB1, Gβ1) were upregulated in Gsp+ tumors (Figure 3C, Table 4). The CaCn 305 
members, calcium voltage-gated channel subunit alpha 1A and 1E (CACNA1A and CACNA1E) and calcium 306 
voltage-gated channel auxiliary subunit gamma 2 (CACNG2), were downregulated via hypomethylation 307 
(Supplementary Table S8). 308 
DISCUSSION 309 
Pituitary tumors are slowly growing benign neoplasia with a low mitotic activity due to senescence. Somatic 310 
SNVs and SVs are rarely found in these tumors, indicating that also other mechanisms are driving 311 
tumorigenesis [7, 8, 9, 10, 11, 12]. Aneuploidy is a common feature in solid tumors, and it provides cancer 312 
cells a mechanism to lose tumor suppressors and gain extra copies of oncogenes [13, 14]. However, a causal 313 
relationship between aneuploidy and tumorigenesis as well as genes/pathways that are deregulated by 314 
aneuploidy are still incompletely characterized [27]. Aneuploidy is a relatively common event in 315 
somatotropinomas [8, 12, 28]. In the current study, we were able to confirm that somatotropinomas create two 316 
subtypes associated with distinct aneuploidy rates and unique transcription profiles. The CA-tumor subtype 317 
contained Gsp- tumors characterized by frequent and recurrent aneuploidy. Recurrent aneuploidy has been 318 
associated earlier with more malignant tumors [29], suggesting a selective advantage and role in the tumor 319 
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evolution in these cancer types. The other subtype, CS-tumors, contained all Gsp+ tumors together with two 320 
Gsp- adenomas. These tumors were either totally aneuploidy-free or displayed only single chromosome 321 
number changes, indicating that expression changes caused by chromosome copy number alterations are 322 
poorly tolerated in this tumor subtype. 323 
In some tumor types, aneuploidy is associated with increased malignant potential, tumor recurrence, and drug 324 
resistance [13, 14]. In the current study, clinical features of the patients (Supplementary Table S2) did not 325 
associate with aneuploidy. Moreover, larger studies have shown that there is no difference in clinical 326 
characteristics and outcome of the patients with or without Gsp mutation [6, 19], indicating that most aneuploid 327 
Gsp- tumors do not progress towards aggressive disease. 328 
Because GH-secreting cells constitute only up to 45% of normal anterior pituitary cells [30] and because tumor 329 
groups had their own expression signatures (Figure 1A), expression profile comparison was performed 330 
between CA- and CS-tumor groups. Moreover, there was not normal anterior pituitary lobe tissue available for 331 
the study. Differentially expressed genes in CA- and CS-tumors enriched most significantly in the PKA 332 
signaling. It is well established that oncogenic Gsp mutations activate the cAMP-dependent PKA pathway [5]. 333 
Therefore this result reflects the Gsp+ tumor-induced activation of PKA signaling in the CS-tumor group. In 334 
addition to the previously Gsp+ tumor - associated molecules, e.g. cAMP-specific PDEs [19], we found that 335 
many protein tyrosine phosphatase (PTPs) receptors were differentially expressed in CA- and CS-tumor 336 
groups. Moreover, PTPRD and PTPRK IHCs showed elevated protein levels in Gsp+ tumors. PTPs are known 337 
to regulate crosstalk between cAMP and the mitogen-activated protein (MAP) kinase cascade [31], and 338 
abundant enrichment of these genes imply the role for the PTP-signaling in the tumorigenesis of Gsp+ 339 
adenomas. 340 
RB1/E2F complex has a major role in the cell cycle regulation. It controls the G1/S phase transition during the 341 
cell cycle and is regulated by the RB1 pocket proteins (RB1, RBL1/p107, RBL2/p130) and E2F transcription 342 
factors. Dysregulated G1/S-phase transition promotes tumor formation and may give rise to aneuploidy. 343 
Inactivation of RB1 through phosphorylation leads release of E2F transcription factors and subsequent cell 344 
cycle progression. RB1/E2F complex has shown to be involved in pituitary tumorigenesis. RB1 is a tumor 345 
suppressor and mice with heterozygous inactivating Rb1 mutation develop pituitary adenomas [20, 32, 33]. 346 
Our expression data showed that RB1/E2F-mediated G1/S –checkpoint signaling is differentially regulated 347 
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between the tumor groups. The CA-tumor group displayed downregulation of E2F4, whereas E2F-repressors 348 
HDAC5 and RBL1/p107 [34] were upregulated. E2F4 is traditionally categorized as a transcriptional repressor, 349 
but more recently it was shown that in some tissue types E2F4 may act as an activator of proliferation [35]. 350 
The function of E2F4 in GH-secreting pituitary cells is not elucidated. Interestingly, apart from HDAC5 351 
(17q21), all differentially expressed G1/S- related genes, E2F4 (16q22), RBL1 (20q11), and TGF-β2 (1q41), 352 
SMAD3 (15q.22) locate on chromosomes with recurrent aneuploidy and their expression correlated with the 353 
direction of aneuploidy (Supplementary Fig. S1).We did not observed differences in protein levels of tot- and 354 
phospho-RB1 between CA- and CS-tumor groups. Immunohistochemistry is, however, a semiquantitative 355 
method and do not necessary detect more subtle protein level differences. 356 
The pituitary tumor-transforming 1 gene (PTTG1) (5q33) is a mitotic checkpoint protein which regulates a 357 
sister chromatid segregation during mitosis as well as genes encoding G1/S and G2/M phase proteins [36, 37, 358 
38]. RNA and protein levels of PTTG1 exhibit a cell cycle–dependent expression pattern, being highest at 359 
G2/M phase and attenuated after mitosis. PTTG1 is expressed in all types of pituitary tumors [39, 40]. Mice 360 
with overexpressed Pttg1 develop pituitary adenomas, whereas knockout Pttg1-/- animals do not [41, 42]. 361 
Crossbreeding of overexpressed Pttg1 animal with heterozygous Rb1+/- mice increased penetrance of pituitary 362 
tumors. In contrast, crossbreeding of Pttg1-/- animals with Rb1+/- mice showed decreased tumor number and 363 
size, further supporting cooperative relationship between PTTG1 and RB1 in pituitary tumorigenesis [41, 42, 364 
43]. It has also shown that both loss and overexpression of PTTG1 promote aneuploidy and G1/S cell cycle 365 
arrest induced senescence [43, 44, 45]. 366 
We showed that CA-tumors with recurrent aneuploidy exhibit higher PTTG1 protein levels. This finding 367 
together with the known function of PTTG1 in pituitary tumorigenesis [36, 39, 41, 43, 44] may indicate that 368 
elevated PTTG1 levels are involved in the development of aneuploidy in CA-somatotropinomas. During the 369 
initial steps of tumorigenesis, slowly accumulating aneuploidy can mediate excessive proliferation by 370 
changing gene expressions and modulating functions of pituitary tumor driver pathways. Eventually, however, 371 
recurrent aneuploidy leads to mitotic stress and senescence via altered levels of proteins involved in the 372 
RB1/E2F– mediated G1/S cell cycle progression. Thus, in CA-somatotropinomas aneuploidy may underlie 373 
both the tumor formation as well as escape from aggressive growth and malignancy. 374 
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Interestingly, PTTG1 seems to be a downstream target of E2F transcription factor family [33]. However, the 375 
regulatory mechanisms of PTTG1 are only partially elucidated and further studies are required in order to 376 
evaluate the role of PTTG1 in pituitary tumorigenesis. 377 
Alterations of DNA methylation have been recognized as an important component of tumor development and 378 
progression of cancer through different mechanisms. It has been shown, that pituitary tumors have their own 379 
distinct DNA methylation profile without overlapping with other sellar region tumors [12]. The current work 380 
shows that DNA methylation of somatotropinomas tends to cluster according to the Gsp mutation status. DNA 381 
methylation levels can have longitudinal changes due to epigenetic reprogramming during tumorigenesis [46], 382 
which may explain the observed mis-clusterd tumors in our sample set. In general, Gsp+ tumors were 383 
hypomethylated when compared to Gsp- tumors and distributions of methylation levels for different genomic 384 
contexts across tumors revealed distinct Gsp genotype-specific methylation profiles. DNMT1 is a 385 
methyltransferase enzyme, which maintains DNA methylation during cell replication. Aberrant expression of 386 
DNMT1 is involved in tumor transformation and progression in many cancer types [22, 47]. In the present 387 
study, expression of DNMT1 was found to be positively correlated with tumor-specific methylation levels, 388 
indicating involvement of DNMT1 in the somatotropinoma tumorigenesis through establishment of 389 
methylation levels. 390 
Gsp genotype-specific DNA methylation profiles indicate that different molecular mechanisms are involved 391 
in the development and progression of Gsp+ and Gsp- pituitary tumors. The integration of DNA methylation 392 
and gene expressions demonstrated that the inhibitory Gα protein (Gαi) signaling, together with the voltage-393 
gated calcium channel (CaCn) transducer signaling are the major biological functions differentially regulated 394 
via DNA methylation in these tumor subtypes. In Gsp+ tumors Gαi signaling was activated through 395 
overexpression of Gαi-2 (GNAI2) and Gβ1 (GNB1), whereas CaCn subunits were downregulated. Both of these 396 
signaling cascades are involved in the regulation of cAMP response. Inhibitory Gαi proteins most notably 397 
inhibit receptor-dependent cAMP synthesis [48]. CaCn signaling stimulates the cAMP response element-398 
binding (CREB) protein, a main downstream target of mitogenic effect of cAMP [26, 49, 50]. Thus, activated 399 
Gαi and downregulated CaCn emphasize the adaptive response to elevated cAMP levels caused by GNAS (Gαs) 400 
mutation and hereby likely prevents the excessive cellular proliferation in Gsp+ tumors. We have earlier shown 401 
that dysfunctional Gαi signaling and particularly the reduced Gαi-2 protein levels contribute to the development 402 
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of AIP germline mutation associated somatotropinomas [25]. This study, however, shows for the first time the 403 
essential role of Gαi signaling in Gsp+ somatotropinomas with constitutively activated cAMP synthesis. 404 
The systematic characterization of the somatic landscape using genomic, epigenomic, and transcriptomic data 405 
across Gsp+ and Gsp- somatotropinomas highlighted tumor subtypes and subtype-specific mechanisms of 406 
tumorigenesis. The study suggest association between increased PTTG1 protein levels and aneuploidy in Gsp-407 
adenomas, whereas Gsp+ tumors are characterized by DNA methylation controlled Gαi – CaCn signaling, a 408 
response to the mitogenic cAMP-signaling caused by GNAS mutation. While further studies are needed to fully 409 
characterize the molecular mechanisms resulting from aneuploidy-induced pituitary tumorigenesis, the work 410 
presented here provides valuable new information about subtype-specific pituitary tumorigenesis. Moreover, 411 
these findings may help to elucidate the mechanisms of aneuploidy also in other tumor types.  412 
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 Table 1. Characteristics of the patients. IGF-1 and PRL levels at diagnosis were compared to age- and sex-
matched upper normal limits 




























 ST2a 43/M GH 329  macro R201C 1 no NA 4.9 0.9±0.17 0.5±0.21 
 ST3a 37/M GH/PRL 458 1340 macro R201C 2 yes yes 0 3.8±0.44 0.6±0.19 
 ST4a 69/F GH 207  micro R201C 1 no no 22 1.7±0.4 0.5±0.39 
 ST5a 56/M GH 177  macro - 1 no no 0 2.4±0.7 1.1±0.32 
 ST6a 40/M GH 313  macro - 1 yes yes 0 1.9±0.35 0.9±0.12 
 ST7a 40/F GH 189  macro - 2 yes NAb 34.1 3.5±0.31 1.7±0.38 
 ST8a 55/F GH 187  macro - 1 no NA 34.1 1.2±0.44 0.9±0.40 
 ST9a 38/F GH 202  macro - 1 no no 41.5 3.4±0.77 0.9±0.24 
 ST10a 14/M GH 14  macro - 1 no no 41.5 6.4±0.71 3.1±0.44 
 ST11a 24/F GH 138  macro - 2 yes no 43.9 1.8±0.54 1±0.34 
 ST12a 37/M GH 305  macro - 2 no yes 58.5 0.5±0.46 0.3±0.13 
 ST13 40/M GH 247  macro - 1 no yes 32.1 1.4±0.47 1.7±0.43 
 ST14 59/M GH NA  NA R201C 1 no NA 0 0.5±0.45 0.7±0.26 
 ST15 62/F GH 374  macro R201C 1 no NA 5.1 1.4±0.48 0.6±0.31 
 ST16 59/M GH 57  macro - 1 no yes 43.6 1.0±0.42 1.7±0.27 
 ST17 45/M GH 38  macro Q227L 1 no yes 0 0.6±0.19 0.8±0.22 
 ST18 26/F GH 78  macro - 1 no no 46.2 4.1±0.64 2.6±0.30 
 ST19 53/F GH 177  macro - 1 no yes 10.3 2.7±0.35 3.7±0.40 
 ST20 44/M GH 135  micro -  1 no no 46.2 3.1±0.30 2.6±0.52 
 ST21 34/M GH 274  macro Q227L 1 no yes 2.6 2.8±0.44 2.1±0.49 
 ST22 37/M GH 234  macro - 1 no nob 25.6 1.9±0.37 1.5±0.39 
Abbreviation: M, male; F, female; GH, growth hormone; PRL, prolactin; IGF-1, insulin-like growth factor 1; 574 
% of UNL, percent increase compared to upper normal limit; Gsp status, mutation observed; GI, genetic 575 
instability; PTTG1, pituitary tumor transforming gene 1. aWGS and SCNA data of tumors published in 576 
Välimäki et al. [8]. NA, not available; bnon-compliant, not in remission   577 
25 
 
Table 2. Differentially expressed genes in the PKA Signaling pathway (CA- vs CS-tumors). 
 
Symbol Entrez Gene Name FC FDR Type 
Symbol in 
Pathway 
AKAP13 A-kinase anchoring protein 13 -2.820 0.017 other AKAP 
CAMK2D 
calcium/calmodulin dependent 




EYA transcriptional coactivator and 
phosphatase 1 -6.640 
0.021 
phosphatase PTP 
NFAT5 nuclear factor of activated T-cells 5 -2.060 0.005 transcription regulator NFAT 
PDE10A phosphodiesterase 10A -2.840 0.042 enzyme PDE 
PDE4D phosphodiesterase 4D -2.660 0.026 enzyme PDE 
PDE7B phosphodiesterase 7B -4.840 0.001 enzyme PDE 
PHKB 
phosphorylase kinase regulatory 
subunit beta -3.370 
0.000 
kinase PHK 
PLCL1 phospholipase C like 1 (inactive) -4.660 0.002 enzyme PLC 
PRKCD protein kinase C delta 3.310 0.035 kinase PKC 
PTPRD 
protein tyrosine phosphatase, 




protein tyrosine phosphatase, 




protein tyrosine phosphatase, 




protein tyrosine phosphatase, 




protein tyrosine phosphatase, 




protein tyrosine phosphatase, 




protein tyrosine phosphatase, 




RAP1A, member of RAS oncogene 
family -2.000 0.013 enzyme RAP1 
RYR2 ryanodine receptor 2 -7.880 0.001 ion channel RYR 
SMAD3 SMAD family member 3 -8.770 0.011 transcription regulator SMAD3 
TCF4 transcription factor 4 -2.450 0.013 transcription regulator TCF/LEF 
TGFB2 transforming growth factor beta 2 -2.120 0.046  growth factor TGF-β 
FC: expression fold change; FDR: false discovery rate 
 




Table 3. G1/S Checkpoint Regulation enriched genes from expression pathway analysis (CA- vs. CS-
tumors). 
 
Symbol Entrez Gene FC FDR Type 
Symbol in 
Pathway 
E2F4 E2F transcription factor 4 -2.230 0.030 transcription regulator E2F 
HDAC5 histone deacetylase 5 2.180 0.004 transcription regulator HDAC 
RBL1 RB transcriptional corepressor like 1 2.080 0.006 transcription regulator RBL1 (p107) 
RBBP8 RB binding protein 8, endonuclease -4.06 0.004 enzyme RBBP8 
SMAD3 SMAD family member 3 -8.770 0.010 transcription regulator SMAD3 
TGF-β2 transforming growth factor-β2 -2.120 0.045 growth factor TGF-β 
FC: expression fold change; FDR: false discovery rate 
  580 
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Table 4. Differentially regulated genes in the CREB Signaling pathway (Gsp+ vs. Gsp-). 




calcium voltage-gated channel subunit 
alpha1 A 
3.77 0.001 ion channel CaCn 
CACNA1E 
calcium voltage-gated channel subunit 
alpha1 E 
1.73 0.019 ion channel CaCn 
CACNG2 
calcium voltage-gated channel auxiliary 
subunit gamma 2 
5.25 0.001 ion channel CaCn 
GNAI2 G protein subunit alpha i2 -1.17 0.016 ion channel Gα/Gαi 
GNB1 G protein subunit beta 1 -1.40 0.021  ion channel Gβ 
eQTMβ: Expression quantitative trait methylation, a correlation between gene expression and 
methylation, FDR: false discovery rate 




Figure 1. A, Gene expression of somatotropinomas clustered according to the aneuploidy rate. Left: Result of 583 
unsupervised hierarchical clustering of expression-array data from 21 somatotropinomas. Middle: Patients’ 584 
age at diagnosis, gender, and Gsp mutation status. Right: Somatic copy-number aberrations. Supplementary: 585 
Fig. S1 shows all somatic chromosomal aberrations in more detail. Of note, the chr 1p of ST3 contains 586 
chromothripsis event [8]. B, Enriched pathways result from differentially expressed genes (CA- vs CS-tumors). 587 
Supplementary Table S4 shows the complete list of significantly (p< 0.05) enriched expression pathways and 588 
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genes. The blue horizontal bars denote the association P-values for each pathway on a logarithmic scale 589 
(dashed vertical line at p=0.05). The ratio between the number of query genes found and total number of genes 590 
in a pathway is shown in orange. C, The enriched G1/S Signaling pathway. The colored molecules identified 591 
as differentially regulated in CA- vs CS-tumor groups. FCs and p-values are listed in Table 3. Orange label=up-592 




Figure 2. The enriched PKA Signaling pathway. The colored molecules identified as differentially expressed 595 
genes or gene groups in CA- vs CS-tumors. FCs and p-values are listed in Table 2. Orange label=up-regulated; 596 




Figure 3. A, CpG methylation of somatotropinomas clustered according to the Gsp mutation status. Left: 599 
Unsupervised hierarchical clustering of CpG methylation data from 21 somatotropinoma samples (based on 600 
50 000 regions with the largest variance between tumors). Middle: Patient’s age at diagnosis, gender, and Gsp 601 
mutation status. Right: Distribution of estimated CpG methylation levels for each genomic context: gene body 602 
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(from +2kb relative to the TSS to the end of gene), promoter (-1kb to +2kb relative to the TSS), CpG 603 
island/shore, enhancer, DNase (DNaseI Hypersensitivity Cluster), and TFBS (Transcription factor cluster) (see 604 
Materials and methods for details). Methylation levels are quantified by value ranging from zero 605 
(unmethylated) to one (fully methylated). B, Pathway analyses from cis-eQTMs. Supplementary Table S10 606 
shows the list of significantly (p< 0.05) enriched cis-eQTM pathways and genes. The blue horizontal bars 607 
denote the association P-values for each pathway on a logarithmic scale (dashed vertical line at p=0.05). The 608 
ratio between the number of query genes found and total number of genes in a pathway is shown in orange. C, 609 
The enriched CREB Signaling in Neurons pathway. The colored molecules identified as differentially 610 
expressed Gsp+ vs Gsp- tumors. eQTM- and FDR-values are listed in Table 4. Orange label=up-regulated; 611 
green label = down-regulated. 612 
